Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,548,609 papers from all fields of science
Search
Sign In
Create Free Account
metopimazine
Known as:
1-(3-(2-methylsulfonylphenothiazin-10-yl) propyl)isonipecotinamide
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Antiemetics
Isonipecotic Acids
Narrower (1)
Vogalene
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Pharmacokinetic study of metopimazine by oral route in children
E. Mallet
,
F. Bounoure
,
M. Skiba
,
É. Saussereau
,
J. Goullé
,
M. Castanet
Pharmacology Research & Perspectives
2015
Corpus ID: 18720899
Metopimazine (MPZ) is an antiemetic considered as a currently used drug. In France, it has become the leading antiemetic mediator…
Expand
2013
2013
Estimating the excess of inappropriate prescriptions of anti‐dopaminergic anti‐emetics during acute gastroenteritis epidemics in France
Victoire Roussel
,
T. Tritz
,
+7 authors
T. Hanslik
Pharmacoepidemiology and Drug Safety
2013
Corpus ID: 33635113
Anti‐dopaminergic anti‐emetics (ADA) use for the treatment of nausea associated with gastroenteritis (GE) can be considered…
Expand
2008
2008
Comparative impact of three malaria preventive regimens during pregnancy on maternal anemia due to malaria in Burkina Faso
A. Ouédraogo
,
Edith C. Bougouma
,
A. Diarra
,
A. Konaté
,
I. Nebie’
2008
Corpus ID: 115771340
2008
2008
[Tolerance and efficacy of mefloquine as the first line treatment of uncomplicated P. falciparum malaria in children].
P. Valeyre
,
R. Favier
,
M. Adam
,
B. Quinet
,
E. Grimprel
,
N. Parez
Pathologie et biologie
2008
Corpus ID: 22358877
2003
2003
Bioavailability of the antiemetic metopimazine given as a microenema.
J. Herrstedt
,
M. Jørgensen
,
H. Angelo
,
M. Rassing
,
J. Møller-Sonnergaard
,
P. Dombernowsky
British Journal of Clinical Pharmacology
2003
Corpus ID: 29262861
The absorption of the antiemetic metopimazine (MPZ) given as a single dose of (a) 40 mg microenema, (b) 40 mg orally and (c) 10…
Expand
1997
1997
The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French…
B. Lebeau
,
A. Depierre
,
+5 authors
H. d’Allens
Annals of Oncology
1997
Corpus ID: 6224232
BACKGROUND Cisplatin is one of the most effective cytotoxic drugs used in the treatment of certain neoplasms, but is also one…
Expand
1993
1993
Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and alpha 1-adrenergic receptors.
J. Herrstedt
,
J. Hyttel
,
J. Pedersen
Cancer Chemotherapy and Pharmacology
1993
Corpus ID: 25296125
The interactions of the antiemetic metopimazine (MPZ) and of the chemotherapeutic agents, cisplatin, carboplatin, doxorubicin…
Expand
1990
1990
[Treatment of vomiting in infants and children induced by acute infectious pathology. A comparative study of alizapride versus metopimazine].
H. Debray
,
J. Guihard
,
D. Peyramond
,
P. Tron
Annales de pediatrie
1990
Corpus ID: 38620224
The effectiveness and tolerance of alizapride and metopimazine used to treat vomiting induced by acute infectious diseases were…
Expand
1978
1978
Treatment of Nausea and Vomiting Related to Anti-Cancerous Multiple Combination Chemotherapy: Results of Two Controlled Studies
L. Israel
,
C. Rodary
Journal of International Medical Research
1978
Corpus ID: 27746383
Two controlled double-blind studies were carried out successively on a cancerous out-patient population receiving multiple…
Expand
1973
1973
Controlled studies of metopimazine for the treatment of nausea and vomiting.
C. Moertel
,
R. J. Reitemeier
Journal of clinical pharmacology
1973
Corpus ID: 39267754
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE